2-甲基-2-丙基(2S,3S)-2-(羟基甲基)-3-甲基-1-吡咯烷羧酸酯 | 817554-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-甲基-2-丙基(2S,3S)-2-(羟基甲基)-3-甲基-1-吡咯烷羧酸酯
• 英文名称: (2S,3S)-tert-butyl 2-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate
• 英文别名: 1,1-dimethylethyl (2S,3S)-2-(hydroxymethyl)-3-methyl-1-pyrrolidinecarboxylate；tert-butyl (2S,3S)-2-(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate
• CAS: 817554-70-4
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: FPUBEXOAVGKKCY-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基(2S,3S)-2-(羟基甲基)-3-甲基-1-吡咯烷羧酸酯 在 ruthenium trichloride 、 sodium periodate 、 三氟乙酸 作用下， 以 水 、 乙腈 为溶剂， 生成 反式-3-甲基-L-脯氨酸
  参考文献：
  名称：

  Synthesis of homochiral 3-substituted glutamic acids and prolines from pyroglutamic acid

  摘要：

  Efficient syntheses of (2S,3S)-methylproline (5a) and (2S,3R)-phenylproline (5b) are described, starting from the readily available pyroglutaminol derivatives 2a and 2b via conjugate 1-4-addition of organocuprates to 1. Catalytic hydrogenation of 3 from the least hindered alpha-side furnishes 6, which is transformed to (2S,3R)-methylproline (7). 3-Substituted glutamic acids 8c,d are provided by a four step procedure from 2c,d.

  DOI：

  10.1016/s0957-4166(00)86204-7
• 作为产物：
  描述：

  反式-3-甲基-L-脯氨酸 在 N-甲基吗啉 、 sodium tetrahydroborate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.75h， 生成 2-甲基-2-丙基(2S,3S)-2-(羟基甲基)-3-甲基-1-吡咯烷羧酸酯
  参考文献：
  名称：

  Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

  摘要：

  A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding K-i and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both G(q)-coupled intracellular Ca2+ flux and G(s)-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

  DOI：

  10.1021/acs.jmedchem.6b01559

文献信息

• PYRROLIDINE GPR40 MODULATORS
  申请人：Ellsworth Bruce A.

  公开号：US20110082165A1

  公开（公告）日：2011-04-07

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物： 或其立体异构体，或药用可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• [EN] IAP INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：TETRALOGIC PHARMACEUTICAL CORP

  公开号：WO2009094287A1

  公开（公告）日：2009-07-30

  The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated.

  本发明描述了以下式的化合物：它们的制备方法，含有它们的药物组合物，以及它们在治疗中的应用。本发明的化合物抑制IAPs（凋亡抑制蛋白），因此在癌症、自身免疫疾病和其他凋亡缺陷相关疾病的治疗中具有用处。
• Combinatorial Solid-Phase Synthesis and Biological Evaluation of Cyclodepsipeptide Destruxin B as a Negative Regulator for Osteoclast Morphology
  作者：Hiroshi Sato、Masahito Yoshida、Hayato Murase、Hiroshi Nakagawa、Takayuki Doi

  DOI：10.1021/acscombsci.6b00076

  日期：2016.9.12

  Combinatorial synthesis and biological evaluation of cyclodepsipeptide destruxin B have been achieved. The cyclization precursors were prepared by solid-phase peptide synthesis via a split and pool method utilizing SynPhase lanterns with colored tags and cogs, followed by cleavage from the polymer-support. Macrolactonization utilizing MNBA-DMAPO in solution-phase was successfully performed in parallel to afford

  环二肽destruxin B的组合合成和生物学评估已实现。环化前体是通过固相肽合成，使用具有彩色标签和嵌齿轮的SynPhase提灯，通过分体和合并方法制备的，然后从聚合物载体上裂解下来的。在溶液相中成功并行利用MNBA-DMAPO进行了大环内酯化，以中等至良好的收率提供了所需的64元destruxin类似物。合成类似物的生物学评估表明，构件A的MeAla残基需要诱导破骨细胞样多核细胞（OCL）的所需形态变化，并在R 4处引入取代基 形态可容忍脯氨酸部分的位置，并且可以使破骨细胞中用于靶标识别的分子探针的制备成为可能。
• [EN] GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS<br/>[FR] COMPOSES DE QUINAZOLINE SUBSTITUES PAR GUANIDINO CONSTITUANT DES AGONISTES DE MC4-R
  申请人：CHIRON CORP

  公开号：WO2004112793A1

  公开（公告）日：2004-12-29

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

  提供了一系列含有胍基的小分子化合物，能够作为MC4-R激动剂。当这些化合物被给予受试者时，它们对治疗MC4-R介导的疾病是有用的。这些化合物具有结构IA、IB和IC，其中变量的值在此定义。
• DIMERIC IAP INHIBITORS
  申请人：Condon M. Stephen

  公开号：US20080020986A1

  公开（公告）日：2008-01-24

  Smac mimetics that inhibit IAPs.

  Smac模拟物，抑制IAPs。